Keratoconus is an eye disease, where the thickness of the cornea is reduced and the shape becomes increasingly irregular. These changes result in a progressive vision loss which cannot be compensated anymore, even with glasses.
The objectives of the treatment are both an improvement of vision and the termination of the progression of the disease.
... the latest technology for the treatment of keratoconic eyes where visual acuity is already impaired.
CISIS/MyoRing is the first and only technology which can achieve an improvement of vision and a termination of the progression of the disease. It is as permanent as laser treatment and as safe as contact lenses.
In keratoconic eyes suffering from already impaired vision, MyoRing treatment can improve the vision significantly. MyoRing is a complete ring made for an implantation into the cornea with the ability to eliminate irregularities within the diseased cornea. Due to its patented design as a complete ring implant, the MyoRing can also support the weakened cornea and therefore stop the progression of the disease.
The treatment is a short and minimally-invassive procedure performed under topical anesthesia (eye drops) only. It is free of pain (pre-operatively as well as post-operatively) and the tiny wound heals within a few hours without the need of a suture. No eye patch. No suture. MyoRing keratoplasty is among the safest surgical procedures in ophthalmology and can replace both contact lenses and corneal transplants in most cases.
MyoRing treatment is indicated
... the latest technology for the treatment of keratoconic eyes where the disease is progressing but visual acuity is still sound.
KERALUX Crosslinking allows a homogenous energy transfer even in the steepest and most affected areas of the cornea.
Safe and effective: Conventional corneal crosslinking is a globally accepted therapy of keratoconus. The intention of corneal crosslinking is to stop the progression of the disease by stiffening the cornea. In order to achieve this, 5.4 J/cm2 of energy have to be transferred to the corneal tissue via UV-A light irradiation. In conventional crosslinking, the effective energy transferred to a certain point of the cornea depends on its steepness. Since the steepness of the cornea varies in keratoconic eyes and from patient to patient, conventional crosslinking is not able to provide the right amount of UV-A irradiation to all parts of the cornea. Unfortunately, this is particularly true for the steepest and most affected areas of the cornea. Treatment failure rates of up to 15% are reported.
KERALUX Crosslinking is a new technology, which is able to ensure a homogenous UV-A energy transfer to all parts of the cornea, independent from its steepness. This is achieved by an irradiation channel, which reflects the UV-A irradiation and guarantees a homogenous energy transfer, rather than a free irradiation path used in conventional crosslinking.